ISRCTN12458940进行中（未招募）1 期
A Phase I/II, study of autologous CD34+ haematopoietic stem cells transduced ex vivo with CD11B lentiviral vector encoding human IDS tagged with ApoEII in patients with neuronopathic mucopolysaccharidosis type II (nMPS II, Hunters syndrome)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Written informed consent from a legally authorized guardian
- •2. Male, age at consent =3 months and =12 months
- •3. Normal cognitive function or mild cognitive dysfunction (patient has a Development Quotient [DQ] score =70 at screening as determined by the Bayley Scale of Infant Development-third edition (BSID-III), cognitive domain), or assessed as normal or only mildly impaired by experienced neuropsychologist
- •4. Close male relative with known severe (progressive neuronopathic) phenotype of MPSII, or genotype associated with progressive neuronopathic phenotype. This is to be confirmed by the independent expert reviewers.
- •5. IDS activity =10% of the Lower Limit of Normal as measured in leucocytes or plasma, plus either:
- •5.1. A normal enzyme activity level of at least one other sulfatase (to rule out multiple sulfatase deficiency) as measured in leucocytes, or
- •5.2. A documented mutation in the IDS gene
- •6. Medically stable and able to accommodate the protocol requirements, including travel without placing an undue burden on the patient/patient’s family, as determined by the CI
- •7. Patients and their parents/legal guardians must be willing and able to comply with study restrictions and to commit to attend clinic for the required duration during the study and follow-up period as specified in the protocol
排除标准
- •1. The patient has previously received stem cell or gene therapy
- •2. The patient has received modified intravenous ERT or intrathecal ERT in a trial setting
- •3. Patient currently enrolled in another interventional clinical trial
- •4. The patient has a history of poorly controlled seizures
- •5. Hemizygous for mutation known to be associated with non-neuropathic phenotype
- •6. The patient is currently receiving psychotropic or other medications which, in the CI’s opinion, would be likely to substantially confound test results
- •7. The patient has received any investigational medicinal product (including Genistein) within 30 days prior to the Baseline visit or is scheduled to receive any investigational medicinal product during the course of the study
- •8. Documented Human Immunodeficiency Virus (HIV) infection (positive HIV RNA and/or anti-p24 antibodies)
- •9. Malignant neoplasia (except local skin cancer) or a documented history of hereditary cancer syndrome. Patients with a prior successfully treated malignancy and a sufficient follow-up to exclude recurrence (based on oncologist opinion) can be included after discussion and approval by the Medical Monitor
- •10. Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome and acute myeloid leukaemia, or other serious haematological disorders
- •11. The patient has a medical condition or extenuating circumstance that, in the opinion of the CI, might compromise the patient’s ability to comply with protocol requirements, the patient’s well-being or safety, or the interpretability of the patient’s clinical data
- •12. Visual or hearing impairment sufficient to preclude adequate neurodevelopmental testing
- •13. Severe behavioural disturbances due to reasons other than MPS II and likely to interfere with protocol compliance, as determined by the CI
- •14. Known sensitivity to Busulfan
- •15. The receipt of live vaccinations within 30 days prior to treatment start
- •16. Known sensitivity to DMSO
研究者
相似试验
进行中（未招募）
1 期
A study testing a gene therapy to treat mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A)EUCTR2019-002051-42-GBniversity of Manchester5
已完成
1 期
A Phase I/ II Clinical Trial: Autologous CD34+ Cell Transplantation for Bone and Vascular Healing in Patients with Non-Union Fractureon-Union FractureJPRN-UMIN000002993Ryosuke Kuroda, M.D., Ph.D.17
已完成
1 期
Autologous peripheral blood-derived CD34+ cell transplantation for acute kidney injury.acute kidney injuryJPRN-UMIN000031691Kidney Disease and Transplant Center, Shonan Kamakura General Hospital9
招募中
1 期
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell DiseaseSickle Cell DiseaseNCT04819841Kamau Therapeutics15
招募中
1 期
CD34+ cell transplantation for patients with acute renal failure.JPRN-jRCTb030190231OHTAKE Takayasu9